PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
26 oct. 2023 13h51 HE
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General...